Pakistan Nears WHO Level 3 Pharma Certification For Global Exports

Pakistan is on the verge of securing World Health Organisation Level 3 certification for its pharmaceutical sector, a milestone that would grant the country's drug manufacturers export eligibility to approximately 150 countries. The certification represents a significant upgrade in regulatory standing for an industry that has long operated below the threshold required for access to high-value regulated markets.

WHO maturity level classifications serve as an internationally recognised benchmark for the quality of a country's medicine regulatory authority. Achieving Level 3 would signal that Pakistan's regulatory framework meets internationally accepted standards for oversight, quality control, and post-market surveillance.

The development holds substantial commercial implications. A certified status would allow Pakistani pharmaceutical companies to compete for tenders in markets currently inaccessible due to regulatory barriers, including major African, Central Asian, and select European markets that require WHO-level assurances before approving imports.

Officials and industry stakeholders have framed the certification push as part of a broader effort to diversify and expand Pakistan's export base beyond traditional commodities. The pharmaceutical sector has been identified in successive national industrial strategies as a priority sector for value-added export growth, and the WHO certification would represent a concrete structural enabler for that ambition.